Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

US. They provide convincing evidence to support their conclusion that using the whole genome, rather than previous use of two surface proteins, enhances our understanding of strain-specific vaccine ...

In March, the Prime Minister Keir Starmer announced plans to scrap NHS England, the public body that oversees the National ...

In EAGLE-2, therapeutic success occurred in 50.6 percent of patients taking ... The approval of Blujepa was granted to GlaxoSmithKline.

GlaxoSmithKline Pharmaceuticals Limited is ... Cefspan (Cefixime - oral antibiotic) was relaunched with good success. Other branded generics launched during the year were Modvate 3 cream ...

GlaxoSmithKline has found a replacement for ... His time at Pfizer has coincided with the spectacular success of its BioNTech-partnered mRNA vaccine for COVID-19 – Comirnaty – and as GSK ...

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

Pfizer is following the example of GlaxoSmithKline and Novartis ... we are creating an executive team that has a proven record of success, an unwavering commitment to the patients we serve ...

In 2012, GlaxoSmithKline agreed to plead guilty ... to file lawsuits on behalf of the government. If the suit is successful, the whistleblower gets to keep a portion of the recovered funds for ...